Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-03-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularqtheartstageuln
  Phrases that lowered it: ovarianfemaleprimaryfallopianplatinum
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Maximum age: 130 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 169 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1289 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 8.1% (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 23.9% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 95.7% (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers NCT06130254 · started 2024 · scored riskier than 70% of active trials terminated
• Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma NCT01035658 · started 2010 · scored riskier than 74% of active trials terminated
• A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours NCT04949425 · started 2021 · scored riskier than 42% of active trials terminated
• Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib NCT05008913 · started 2021 · scored riskier than 13% of active trials terminated
• AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] NCT03366675 · started 2017 · scored riskier than 39% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.